163 related articles for article (PubMed ID: 8740095)
1. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
Kees F; Wellenhofer M; Bröhl K; Grobecker H
Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
[TBL] [Abstract][Full Text] [Related]
2. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers.
Liu YM; Liu Y; Lu C; Jia JY; Liu GY; Weng LP; Wang JY; Li GX; Wang W; Li SJ; Yu C
Clin Ther; 2010 Nov; 32(12):2097-105. PubMed ID: 21118745
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.
Tremblay D; Dupront A; Ho C; Coussediere D; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():21-8. PubMed ID: 2292526
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
Saathoff N; Lode H; Neider K; Depperman KM; Borner K; Koeppe P
Antimicrob Agents Chemother; 1992 Apr; 36(4):796-800. PubMed ID: 1354432
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.
Gehanno P; Andrews JM; Ichou F; Sultan E; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():47-51. PubMed ID: 2292530
[TBL] [Abstract][Full Text] [Related]
8. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution.
Borin MT; Forbes KK; Hughes GS
Biopharm Drug Dispos; 1995 May; 16(4):295-302. PubMed ID: 7548778
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.
Kumar V; Madabushi R; Lucchesi MB; Derendorf H
J Vet Pharmacol Ther; 2011 Apr; 34(2):130-5. PubMed ID: 21395603
[TBL] [Abstract][Full Text] [Related]
10. Effect of food on absorption of cefpodoxime proxetil oral suspension in adults.
Borin MT; Forbes KK
Antimicrob Agents Chemother; 1995 Jan; 39(1):273-5. PubMed ID: 7695323
[TBL] [Abstract][Full Text] [Related]
11. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
12. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil.
Kakumanu VK; Arora V; Bansal AK
Int J Pharm; 2006 Jul; 317(2):155-60. PubMed ID: 16621365
[TBL] [Abstract][Full Text] [Related]
13. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
[No Abstract] [Full Text] [Related]
14. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.
Dumont R; Guetat F; Andrews JM; Sultan E; Lenfant B
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():41-6. PubMed ID: 2292529
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs.
Papich MG; Davis JL; Floerchinger AM
Am J Vet Res; 2010 Dec; 71(12):1484-91. PubMed ID: 21118001
[TBL] [Abstract][Full Text] [Related]
16. Effect of timing of food on absorption of cefpodoxime proxetil.
Borin MT; Driver MR; Forbes KK
J Clin Pharmacol; 1995 May; 35(5):505-9. PubMed ID: 7657851
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
Zuck P; Rio Y; Ichou F
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():71-7. PubMed ID: 2292534
[TBL] [Abstract][Full Text] [Related]
18. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
Brambilla C; Benhamou D; Guérin JC; Kelkel E; Muir JF; Prud'homme A; Taytard A; Fauche A
Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cefpodoxime proxetil in healthy young and elderly volunteers.
Borin MT; Ferry JJ; Forbes KK; Hughes GS
J Clin Pharmacol; 1994 Jul; 34(7):774-81. PubMed ID: 7929873
[TBL] [Abstract][Full Text] [Related]
20. Tissue penetration of cefpodoxime and cefixime in healthy subjects.
Liu P; Müller M; Grant M; Obermann B; Derendorf H
J Clin Pharmacol; 2005 May; 45(5):564-9. PubMed ID: 15831780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
